Candriam S.C.A. Has $11.80 Million Stock Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Candriam S.C.A. boosted its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 24.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 28,544 shares of the company’s stock after buying an additional 5,610 shares during the period. Candriam S.C.A.’s holdings in IDEXX Laboratories were worth $11,801,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. FSA Wealth Management LLC acquired a new position in IDEXX Laboratories during the third quarter valued at $25,000. Retirement Wealth Solutions LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $31,000. Ashton Thomas Securities LLC acquired a new position in IDEXX Laboratories in the 3rd quarter worth about $37,000. Kestra Investment Management LLC acquired a new position in IDEXX Laboratories in the 4th quarter worth about $38,000. Finally, Crews Bank & Trust acquired a new position in IDEXX Laboratories in the 4th quarter worth about $41,000. 87.84% of the stock is owned by institutional investors and hedge funds.

Insider Activity at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the sale, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the topic of several research reports. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Friday. Leerink Partners initiated coverage on IDEXX Laboratories in a research report on Monday, December 2nd. They issued an “outperform” rating and a $500.00 target price on the stock. Leerink Partnrs raised IDEXX Laboratories to a “strong-buy” rating in a research report on Monday, December 2nd. Piper Sandler upped their target price on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Finally, Morgan Stanley decreased their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research note on Wednesday, January 29th. Four equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and a consensus price target of $533.75.

IDEXX Laboratories Stock Performance

IDXX opened at $430.12 on Friday. The stock has a 50-day moving average of $437.37 and a 200-day moving average of $449.72. IDEXX Laboratories, Inc. has a 52-week low of $398.50 and a 52-week high of $574.94. The company has a market cap of $34.98 billion, a PE ratio of 40.31, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.95 and a current ratio of 1.31.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.